What Memantine—an Alzheimer’s Drug—Could Mean for the Future of Autism Studies

A small clinical trial found the strongest response to memantine in autistic youth with elevated glutamate levels in a specific brain region.

Researchers are revisiting glutamate — one of the brain’s primary neurotransmitters — as studies explore whether drugs like memantine, currently approved for Alzheimer’s disease, could help specific subgroups of autistic individuals through targeted NMDA receptor pathways.

For years, autism research has largely focused on behavior: social communication differences, repetitive behaviors, sensory sensitivities and developmental milestones. But a growing body of neuroscience research is pushing scientists deeper into the biology of the autistic brain itself — particularly the role of glutamate, one of the brain’s most important chemical messengers. Now, a new study involving the Alzheimer’s drug memantine is renewing interest in whether targeting glutamate pathways could one day help certain subgroups of autistic people, potentially opening the door to more personalized treatment approaches in autism research.

Glutamate is the brain’s primary excitatory neurotransmitter, meaning it helps n…